The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. (2021)

First Author: McDowell PJ
Attributed to:  United Kingdom Refractory Asthma Stratification Programme (RASP-UK) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(21)00004-7

PubMed Identifier: 33971168

Publication URI: http://europepmc.org/abstract/MED/33971168

Type: Journal Article/Review

Volume: 9

Parent Publication: The Lancet. Respiratory medicine

Issue: 10

ISSN: 2213-2600